Nautilus Biotechnology (NAUT) Cash & Current Investments (2020 - 2026)

Nautilus Biotechnology has reported Cash & Current Investments for 7 years, with the latest figure at $84.0 million in Q2 2026.

• Quarterly Cash & Current Investments fell 43.17% year-over-year to $84.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $84.0 million (down 43.17% YoY) and the FY2025 annual result came in at $103.4 million, down 20.39% from the prior year.
• Cash & Current Investments eased to $84.0 million in Q2 2026 per NAUT's latest filing, from $95.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $324.1 million in Q1 2022 and troughed at $84.0 million in Q2 2026.
• A 5-year average of $170.8 million and a median of $165.3 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 47423.79% in 2022, then tumbled 48.37% in 2023.
• Over 5 years, Cash & Current Investments stood at $184.5 million in 2022, then decreased by 5.99% to $173.4 million in 2023, then dropped by 25.1% to $129.9 million in 2024, then dropped by 20.39% to $103.4 million in 2025, then declined by 18.74% to $84.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $84.0 million, $95.9 million, and $103.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.